David Lawrence, IAS 2021: Liposomal Amphotericin B Deoxycholate for the treatment of HIV-associated Cryptococcal Meningitis

We had the pleasure to meet with David Lawrence (London School of Hygiene and Tropical Medicine, London, UK) to discuss single high-dose liposomal amphotericin based regimen for treatment of HIV-associated Cryptococcal Meningitis.

The abstract entitled: ‘Single high-dose liposomal amphotericin based regimen for treatment of HIV-associated Cryptococcal Meningitis: results of the phase-3 Ambition-cm Randomised Trial’ was presented at IAS 2021 – the 11th International AIDS Society Conference on HIV Science (Virtual).

Questions:

1. Could you tell us a little about HIV-associated cryptococcal meningitis (CM), and its health burden in sub-Saharan Africa? (0:20)
2. What treatment options are recommended for CM and what are their limitations? (0:41)
3. What is the rationale for the use of a single, high-dose of liposomal amphotericin B deoxycholate in this treatment setting? (2:08)

Disclosures: David Lawrence has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed in coverage of IAS 2021 Virtual.